1.Van Schil P, Van Meerbeeck J, Kramer G, Splinter T, Legrand C, Giaccone G, et al. Morbidity and mortality in the surgery arm of EORTC 08941 trial. The European respiratory journal. 2005; 26: 192–7.
2.van Meerbeeck JP, Kramer GW, Van Schil PE, Legrand C, Smit EF, Schramel F, et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. Journal of the National Cancer Institute. 2007; 99: 442–50.
3.Eberhardt WE, Pottgen C, Gauler TC, Friedel G, Veit S, Heinrich V, et al. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE). Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2015; 33: 4194–201.
4.Rajaram R, Correa AM, Xu T, Nguyen QN, Antonoff MB, Rice D, et al. Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non-Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients. Clinical lung cancer. 2020.
5.Douillard JY, Rosell R, De Lena M, Riggi M, Hurteloup P, Mahe MA, et al. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial. International journal of radiation oncology, biology, physics. 2008; 72: 695–701.
6.Lally BE, Zelterman D, Colasanto JM, Haffty BG, Detterbeck FC, Wilson LD. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2006; 24: 2998–3006.
7.Robinson CG, Patel AP, Bradley JD, DeWees T, Waqar SN, Morgensztern D, et al. Postoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy: a review of the National Cancer Data Base. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2015; 33: 870–6.
8.Le Pechoux C, Dunant A, Faivre-Finn C, Thomas PA, Pourel N, Lerouge D, et al. Postoperative Radiotherapy for Pathologic N2 Non-Small-Cell Lung Cancer Treated With Adjuvant Chemotherapy: Need for Randomized Evidence. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2015; 33: 2930–1.
9.Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2011; 6: 244–85.
10.Warth A, Muley T, Meister M, Stenzinger A, Thomas M, Schirmacher P, et al. The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2012; 30: 1438–46.
11.Leeman JE, Rimner A, Montecalvo J, Hsu M, Zhang Z, von Reibnitz D, et al. Histologic Subtype in Core Lung Biopsies of Early-Stage Lung Adenocarcinoma is a Prognostic Factor for Treatment Response and Failure Patterns After Stereotactic Body Radiation Therapy. International journal of radiation oncology, biology, physics. 2017; 97: 138–45.
12.Spoelstra FO, Senan S, Le Pechoux C, Ishikura S, Casas F, Ball D, et al. Variations in target volume definition for postoperative radiotherapy in stage III non-small-cell lung cancer: analysis of an international contouring study. International journal of radiation oncology, biology, physics. 2010; 76: 1106–13.
13.Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2007; 2: 706–14.
14.Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet. 1998; 352: 257–63.
15.Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzales-Larriba JL, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. The Lancet Oncology. 2006; 7: 719–27.
16.Wei S, Xie M, Tian J, Song X, Wu B, Liu L. Propensity score-matching analysis of postoperative radiotherapy for stage IIIA-N2 non-small cell lung cancer using the Surveillance, Epidemiology, and End Results database. Radiation oncology. 2017; 12: 96.
17.Shen WY, Ji J, Zuo YS, Pu J, Xu YM, Zong CD, et al. Comparison of efficacy for postoperative chemotherapy and concurrent radiochemotherapy in patients with IIIA-pN2 non-small cell lung cancer: an early closed randomized controlled trial. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology. 2014; 110: 120–5.
18.Le Pechoux C. Role of postoperative radiotherapy in resected non-small cell lung cancer: a reassessment based on new data. The oncologist. 2011; 16: 672–81.
19.Asamura H, Chansky K, Crowley J, Goldstraw P, Rusch VW, Vansteenkiste JF, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2015; 10: 1675–84.
20.Groome PA, Bolejack V, Crowley JJ, Kennedy C, Krasnik M, Sobin LH, et al. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2007; 2: 694–705.
21.Chen CY, Wu BR, Chen CH, Cheng WC, Chen WC, Liao WC, et al. Prognostic Value of Tumor Size in Resected Stage IIIA-N2 Non-Small-Cell Lung Cancer. Journal of clinical medicine. 2020; 9.
22.Han H, Zhao Y, Gao Z, Zheng D, Fu F, Zhao Z, et al. A prognostic score system with lymph node ratio in stage IIIA-N2 NSCLC patients after surgery and adjuvant chemotherapy. Journal of cancer research and clinical oncology. 2019; 145: 2115–22.
23.Yoon HY, Lee JC, Kim SW, Kim HR, Kim YH, Choi SH, et al. Prognosis of multi-level N2-positive non-small cell lung cancer according to lymph node staging using endobronchial ultrasound-transbronchial biopsy. Thoracic cancer. 2018; 9: 684–92.
24.Rice SR, Molitoris JK, Vyfhuis MAL, Edelman MJ, Burrows WM, Feliciano J, et al. Lymph Node Size Predicts for Asymptomatic Brain Metastases in Patients With Non-small-cell Lung Cancer at Diagnosis. Clinical lung cancer. 2019; 20: e107-e14.
25.Cai Y, Wu H, Shi X, Dong Y, Chang X, Zhang L, et al. Heterogeneous components of lung adenocarcinomas confer distinct EGFR mutation and PD-L1 expression. BMC cancer. 2020; 20: 148.
26.Tsuta K, Kawago M, Inoue E, Yoshida A, Takahashi F, Sakurai H, et al. The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations. Lung cancer. 2013; 81: 371–6.
27.Qian F, Yang W, Wang R, Xu J, Wang S, Zhang Y, et al. Prognostic significance and adjuvant chemotherapy survival benefits of a solid or micropapillary pattern in patients with resected stage IB lung adenocarcinoma. The Journal of thoracic and cardiovascular surgery. 2018; 155: 1227–35 e2.